Scientists with the Institute of Biomedical Sciences and School of Life Sciences at East China Normal University wrote “Smartphone-controlled optogenetically engineered cells enable semiautomatic glucose homeostasis in diabetic mice” in the April 2017 issue of Science Translational Medicine. The researchers used SpectrumLabs.com’s hollow fiber implants in mice to monitor diabetes through mobile devices.

Mobile health is increasingly patient-centric, as the authors of the paper describe. The scientists applied the use of implant technology and the ever-expanding smartphone capabilities to monitor diabetes in mice. Personalized health tracking is not new to the field, however, the researchers believe the technology they developed closes the limitations previous iterations display.

Abstract: With the increasingly dominant role of smartphones in our lives, mobile health care systems integrating advanced point-of-care technologies to manage chronic diseases are gaining attention. Using a multidisciplinary design principle coupling electrical engineering, software development, and synthetic biology, we have engineered a technological infrastructure enabling the smartphone-assisted semiautomatic treatment of diabetes in mice. Click here to read the article.

 

Spectrum proudly offers proprietary KrosFlo hollow fiber membranes for implant technology to provide a TRUE-to-LIFE response for drug screening and cancer research. Perfectly suited for implantation, the modified Polyvinylidene Difluoride (mPVDF) hollow fiber membrane is biocompatible, resistant to cell adhesion, hydrophobic and resistant to a wide variety of organic solvents, including most aqueous acids and bases.

doi: 10.1126/scitranslmed.aal2298